A prospective, multicentre phase II study comparing the efficacy and safety of second or third-line masitinib + irinotecan vs masitinib + gemcitabine in patients with recurrent/relapsed +/or metastatic head and neck squamous cell carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Jul 2015
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Gemcitabine; Irinotecan
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.
- 04 Sep 2013 New trial record
- 30 Aug 2013 The first patient has been recruited, according to an AB Science media release.